Senti Biosciences is trading 13.92% up in pre-market at $0.38, amid recent merger-related financing disclosures.
- On September 3, 2026, an affiliate of Celadon Partners committed to purchase $2.5 million of common stock at Nasdaq’s minimum price, contingent on merger closing.
- On September 1, 2026, the company authorized a $2 million convertible-note tranche.
- The filings provide the clearest company-specific catalyst for the September 8 pre-market gain, though no reliable source explicitly attributes the move to them; no pre-market volume was provided.